Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy
- 29 November 2013
- journal article
- research article
- Published by Springer Nature in Cancer Microenvironment
- Vol. 8 (2) , 57-64
Abstract
Traditionally, anticancer chemotherapy has been generally considered to be strongly immunosuppressive. However, increasing evidence suggests that certain chemotherapeutic agents rely on the induction of antitumor immune responses, in both experimental animal models and patients with cancer. Many of these chemotherapeutic agents exert immunogenic effects via the induction and release of immunostimulatory “danger” signals from dying cancerous cells when used in low doses. New data suggests that several common chemotherapeutic agents may also display direct stimulating effects on immune cells even when applied in ultra-low concentrations (chemoimmunomodulation). Importantly, it is becoming clear that both immune effector cells and immune regulatory cells can be targeted by various chemotherapeutic agents to produce favorable antitumor immune responses. Therefore, utilizing cancer drugs to enhance host antitumor immunity should be considered a feasible therapeutic approach; and recent characterization of the immunomodulatory mechanisms of anticancer chemotherapy using both new and traditional cytotoxic agents suggests that combinations of these approaches with “classical” immunomodulatory agents could lead to a viable new therapeutic paradigm for the treatment of cancer.Keywords
This publication has 69 references indexed in Scilit:
- Heterogeneity of tumor endothelial cellsCancer Science, 2013
- Immunosuppressive Mechanisms of Regulatory Dendritic Cells in CancerCancer Microenvironment, 2013
- Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growthNature Medicine, 2012
- Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivoCancer Immunology, Immunotherapy, 2012
- Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal miceJournal of Immunotoxicology, 2012
- CD91-dependent programming of T-helper cell responses following heat shock protein immunizationNature Communications, 2011
- Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established MelanomaCancer Research, 2010
- Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control2010
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumorsNature Medicine, 2009
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003